Podcast appearances and mentions of john mcevoy

The Hirschfeld Biograph was a cinema housed within the Hirschfeld Centre, which was opened in Temple Bar in March 1979 by the National Gay Federation. The Biograph, with a max capacity of 55, operated every second Monday and had two screenings. It eventually became a roaring success.The success of the Biograph was down to the efforts of one man, John McEvoy, who ran the Hirschfeld Biograph throughout its almost seven-year history. John brought a great level of commitment and professionalism to the running of the Biograph. We sit down with John to recount those years, and the story behind his beloved Biograph.Resources and articles from John on the Hirschfeld Biograph are available here. Hosted on Acast. See acast.com/privacy for more information.

Tuilleadh ceoil with new albums from David Munnelly, John Wynne and John McEvoy, Chatting with Noelle Lynskey from Shorelines Arts Festival and music from Líadan, Breaking Trad, Bow Brothers, Shannonvale Ceili Band, Breda and Clare Keville, Angelina Carberry and Geraldine King.

While the Labour Party may have triumphed in the recent British parliamentary elections, the real victors may have been Israel. Israel and its lobby have deep connections to the British Labour Party, headed by Sir Keir Starmer, and are likely pleased to see him come to power.On today's episode of “The Watchdog,” Lowkey is joined by John McEvoy to discuss his work uncovering Israel's surprisingly firm grip over the British political system. John McEvoy is an investigative journalist for Declassified UK, a media outlet covering British foreign policy and intelligence agencies' true role around the world. While Labour has achieved a landslide victory, McEvoy warns that this was not because of widespread public support. Instead, it was down to a split in the vote between the Conservatives and their far-right challengers, Reform U.K. And while the public yearns for change, Starmer has been steadfast in his refusal to adopt bold policies to deliver what the people want. “Keir Starmer is poised to destroy a lot of hopes of British people and those who have wrongly invested their hopes in him. And that's a recipe for political disaster and a wider shift to the right here,” McEvoy told Lowkey. Perhaps even more worrying is the level of Israeli influence within the Labour Party. Pro-Israel money has flooded in; more than half of the new cabinet has been bankrolled by the British pro-Israel lobby, McEvoy's recent study revealed.Starmer has repeatedly refused to condemn Israel or do anything to concretely support a ceasefire in Gaza. His Labour Party has also elevated some of the most shameless propagandists into key positions. One example is Luke Akehurst, the former director of the pressure group, We Believe in Israel. Throughout its bombardment of Gaza, the U.K. has remained one of Israel's closest allies. Arms exports have increased since October 7, and London has continued to provide diplomatic cover for the genocide. Moreover, British spy planes continue to fly over Gaza, while military supply planes have made dozens of trips to Israel since the bombardment began, making Britain an accomplice in war crimes.Support the Show.The MintPress podcast, “The Watchdog,” hosted by British-Iraqi hip hop artist Lowkey, closely examines organizations about which it is in the public interest to know – including intelligence, lobby and special interest groups influencing policies that infringe on free speech and target dissent. The Watchdog goes against the grain by casting a light on stories largely ignored by the mainstream, corporate media.Lowkey is a British-Iraqi hip-hop artist, academic and political campaigner. As a musician, he has collaborated with the Arctic Monkeys, Wretch 32, Immortal Technique and Akala. He is a patron of Stop The War Coalition, Palestine Solidarity Campaign, the Racial Justice Network and The Peace and Justice Project, founded by Jeremy Corbyn. He has spoken and performed on platforms from the Oxford Union to the Royal Albert Hall and Glastonbury. His latest album, Soundtrack To The Struggle 2, featured Noam Chomsky and Frankie Boyle and has been streamed millions of times.

While the Labour Party may have triumphed in the recent British parliamentary elections, the real victors may have been Israel. Israel and its lobby have deep connections to the British Labour Party, headed by Sir Keir Starmer, and are likely pleased to see him come to power.On today's episode of “The Watchdog,” Lowkey is joined by John McEvoy to discuss his work uncovering Israel's surprisingly firm grip over the British political system. John McEvoy is an investigative journalist for Declassified UK, a media outlet covering British foreign policy and intelligence agencies' true role around the world. While Labour has achieved a landslide victory, McEvoy warns that this was not because of widespread public support. Instead, it was down to a split in the vote between the Conservatives and their far-right challengers, Reform U.K. And while the public yearns for change, Starmer has been steadfast in his refusal to adopt bold policies to deliver what the people want. “Keir Starmer is poised to destroy a lot of hopes of British people and those who have wrongly invested their hopes in him. And that's a recipe for political disaster and a wider shift to the right here,” McEvoy told Lowkey. Perhaps even more worrying is the level of Israeli influence within the Labour Party. Pro-Israel money has flooded in; more than half of the new cabinet has been bankrolled by the British pro-Israel lobby, McEvoy's recent study revealed.Starmer has repeatedly refused to condemn Israel or do anything to concretely support a ceasefire in Gaza. His Labour Party has also elevated some of the most shameless propagandists into key positions. One example is Luke Akehurst, the former director of the pressure group, We Believe in Israel. Throughout its bombardment of Gaza, the U.K. has remained one of Israel's closest allies. Arms exports have increased since October 7, and London has continued to provide diplomatic cover for the genocide. Moreover, British spy planes continue to fly over Gaza, while military supply planes have made dozens of trips to Israel since the bombardment began, making Britain an accomplice in war crimes.Support the Show.The MintPress podcast, “The Watchdog,” hosted by British-Iraqi hip hop artist Lowkey, closely examines organizations about which it is in the public interest to know – including intelligence, lobby and special interest groups influencing policies that infringe on free speech and target dissent. The Watchdog goes against the grain by casting a light on stories largely ignored by the mainstream, corporate media.Lowkey is a British-Iraqi hip-hop artist, academic and political campaigner. As a musician, he has collaborated with the Arctic Monkeys, Wretch 32, Immortal Technique and Akala. He is a patron of Stop The War Coalition, Palestine Solidarity Campaign, the Racial Justice Network and The Peace and Justice Project, founded by Jeremy Corbyn. He has spoken and performed on platforms from the Oxford Union to the Royal Albert Hall and Glastonbury. His latest album, Soundtrack To The Struggle 2, featured Noam Chomsky and Frankie Boyle and has been streamed millions of times.

Tuilleadh ceoil agus amhrán from Carlos Sweeney & McCartin. Mary Mc Namara , Sorcha Costello, David Sanders  songs from Sean Keane, Ger O'Donnell and Adrienne O Shea, tunes from new albums. Tara Howley, Elaine Reilly, John Wynne & John McEvoy agus go leor eile!   

In this week's episode, our host, Sarah Travers, is joined by John McEvoy, Executive Chairman and Co-owner of Duality Healthcare.

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) chief legal officer John McEvoy joins Proactive's Stephen Gunnion with news that POLB 001's Immuno-modulator II has received the fully granted patent from the US Patent Office. McEvoy explained the patent encompasses a class of drugs for treating and preventing hypercytokinemia (cytokine storms) in patients triggered by an immune response, applicable across multiple disease indications. The granted patent further solidifies Poolbeg Pharma's robust intellectual property portfolio for POLB 001, potentially increasing the asset's value and making it more attractive to potential partners. McEvoy highlighted the company's ongoing efforts to strengthen and expand their IP portfolio, noting existing patents covering p38 MAP kinase inhibitors for influenza treatment and hypercytokinemia. Additional patents have been filed, particularly focusing on cancer immunotherapy applications of POLB 001. The company has also applied for patents concerning dosage regimens based on results from their recent LPs trial, aiming to protect innovations and maintain a competitive edge in the pharmaceutical market. This strategic IP protection is crucial for safeguarding the company's products and ensuring shareholder value, particularly as they seek partnerships to further develop POLB 001. #PoolbegPharma, #POLB001, #Immunomodulator, #USPatentOffice, #IntellectualProperty, #Pharmaceuticals, #CytokineStorm, #Hypercytokinemia, #PatentGranted, #DrugDevelopment, #MedicalInnovation, #CancerImmunotherapy, #InfluenzaTreatment, #PharmaIndustry, #JohnMcEvoy, #HealthcareNews, #Biotech, #ClinicalTrials, #PharmaPartnerships, #MedicalResearch #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Agave spirits have been around for at least a few hundred years and within that time they've traveled, they've evolved,  they've been prosecuted by the authorities, they've been neglected by modernity and finally, just around 25 years ago, they started to win the hearts of the spirits and cocktail nerds. Now mezcal is a global phenomena, but to be absolutely honest, that is rather surprising. So I've been tracking some of the people that arrived at this scene right when things were starting to change. In this episode I was lucky enough to have John McEvoy as an invitee. He was there when nobody could explain what mezcal was at gringo bars, when bottles had hotmail emails stamped on their sides, and even decided to invest in the category when it  was unlikely for mezcal to secure any growth. Without further adieu please welcome John, better known as Mezcal PhD. 

9/11 is a date that will live in infamy. But for much of the world, September 11 conjures up images of another deadly assault against freedom and liberty. Exactly 50 years ago today, the democratically-elected socialist president of Chile, Salvador Allende, was overthrown in a far-right military coup led by General Augusto Pinochet.Today, “Watchdog” host Lowkey talks to two guests who know the story of “the First 9/11” better than almost anyone. Roberto Navarette was a 17-year-old medical student at the time of the coup, and was imprisoned – like tens of thousands of his countrymen – in open air stadiums. He survived being tortured and shot by the regime, and eventually escaped, settling in the United Kingdom.Ironically, the U.K. government had actually been working very hard to ensure Allende's downfall, and later to keep Pinochet in power, as John McEvoy's work has revealed. Based on documents obtained under Freedom of Information laws, McEvoy has shown how the U.K.'s MI6 had been training Latin American police and militaries in torture tactics and other ways in which to suppress domestic dissent. Britain had long had strong economic interests in the region, considering it an unofficial part of its empire. McEvoy is an academic, historian and journalist specializing in uncovering Britain's relationship with Latin America. He is currently producing a documentary film – “Britain and the Other 9/11” about the U.K. government's covert campaign against Allende and its subsequent support for Pinochet.Today, Lowkey speaks to Navarette and McEvoy about the coup and its legacy on the world.Allende was a particular threat to the establishment in Washington and London. Not simply because he was a Marxist head of state, but because he was democratically elected and believed in coming to power through entirely legal means. This, for Navarette, terrified many in the West, as it undermined completely their claims about socialism being an anti-democratic ideology. The 1973 coup reverberated around the world. Not only did it become the blueprint for further U.S.-backed operations in Latin America, but Chile became a laboratory for neoliberal economics. The country was flooded with economists from the University of Chicago, who promised to transform it into a modern utopia.Instead, the nation was ruined, with economic crashes and total devastation for ordinary Chilean citizens. The rich, along with foreign corporations made out like bandits, and neoliberalism began to be adopted wholesale across the world, leading to the rampant inequality that plagues the planet today.Support the showThe MintPress podcast, “The Watchdog,” hosted by British-Iraqi hip hop artist Lowkey, closely examines organizations about which it is in the public interest to know – including intelligence, lobby and special interest groups influencing policies that infringe on free speech and target dissent. The Watchdog goes against the grain by casting a light on stories largely ignored by the mainstream, corporate media.Lowkey is a British-Iraqi hip-hop artist, academic and political campaigner. As a musician, he has collaborated with the Arctic Monkeys, Wretch 32, Immortal Technique and Akala. He is a patron of Stop The War Coalition, Palestine Solidarity Campaign, the Racial Justice Network and The Peace and Justice Project, founded by Jeremy Corbyn. He has spoken and performed on platforms from the Oxford Union to the Royal Albert Hall and Glastonbury. His latest album, Soundtrack To The Struggle 2, featured Noam Chomsky and Frankie Boyle and has been streamed millions of times.

In this episode, Matt Blank sits down with John McEvoy. Blank and John take a deep dive into BASE jumping student progression and what it means to be on the path to mastery. John shares his incredible story of recovery, determination, and passion. He talks about how he got into BASE jumping, what he learned from his stroke, how he fixed his heart and faced his tumor, and how he continued to develop his business and teaching. He also reveals some of the challenges and rewards of being a BASE jumper, such as dealing with fear, injuries, and navigating ethics. He shares some of his insights and tips on how to progress safely and responsibly in the sport. John is not only an amazing athlete, but also an inspiring teacher who lives life to the fullest and encourages others to do the same. . McEvoy's links: @johnny_craic @basegear BASEgear.net Baseguiding.com  . Please support this independent project by visiting: https://www.buymeacoffee.com/exitpoint . https://www.exitpointpodcast.com

Trump's recent candor about his push for regime change in Venezuela to secure access to oil proved that US support for the so-called interim government was never about democracy or human rights. It was always about imperialism and the neocolonial drive for the control of Venezuela's resources. While the prospects of the US-backed opposition taking political power by force fizzled out swiftly, another plan has remained firmly in motion: the plunder of Venezuelan foreign assets.VA's Ricardo Vaz joins host José Luis Granados Ceja to talk about US efforts to keep the so-called interim government alive and its role as an instrument to facilitate the plunder of Venezuela's assets and resources. We then talk with investigative journalist John McEvoy to look at the status of Venezuela's gold in the UK and the political efforts by the UK's political establishment to deny the government access to it.Music: Armando Martinez - Mi Patria SoberanaEmbandolaos - Los Caimanes Negros

Resistance TV: Chris Williamson, Journalist John McEvoy and Prof George Lambie.There is so much propaganda about the role and impact of global corporate capitalism and trickle down economics, the truth is often lost in a fog of misinformation. Latin American nations in particular have been at the sharp end of neoliberal orthodoxy and they've also been at the forefront of the resistance to it. This Wednesday, on Resistance TV, two experts of the subject, Journalist John McEvoy and Prof George Lambie, will join Chris Williamson to discuss what the implications have been and the lessons for the UK.Resistance TV is a weekly show hosted by Chris Williamson the former Labour MP, Derby Council Leader and the founder of Resist Movement for a People's Party. With a socialist take on things we look at areas of concern for the left wing, Anti Racism, Anti Imperialism, MMT, Injustice, Britain's role in foreign affairs, 21st century Socialism, Alternative Media and more…Live Wednesday's on all our Social Media at 7pm and audio Podcast on Friday'sJoin Resist here: www.resistmovement.org.ukFollow Chris on Twitter @DerbyChrisW

http;//www.copperplatemailorder.com                                         Copperplate Time 401                                     Presented by Alan O'Leary                               www.copperplatemailorder.com 1. Bothy Band:   Green Groves of Erin/Flowers of Red Hill.   After Hours 2. Garadice:            Gan Ainm/Sunny Hills of Beara/The Castleblamey Piper.   Garadice    3. Andy McGann & Paul Brady:         Dr Gilbert/Concert Reel/Mullin's Fancy.     It's A Hard Road to Travel 4. Billy McComiskey:              Way to Shercock/Nell Davey's Reel .  Outside the Box 5. Niamh Parsons & Loose Connections:                     The Tinkerman's Daughter. Loosely Connected 6. The Teetotalers:  Green Fields of Woodford/The Nightingale/The Castle.                    The Burren Backroom Series Vol 1 7. Gerry O'Connor: Iniscaltra/Tonn Teine/Ormond Sound.                  No Place Like  Home 8. Goitse:  The House on the Hill .   Rosc 9.  Sean Keane: The Man from Connemara. Burren Backroom Series Vol 1 10. Ciara O'Sullivan:    Lord Galway's Lamentation/The Broken Pledge.                   Clare Horizons 11. John McEvoy:   The Flat House/Moal Mountain/The Limestone Rock.                John McEvoy & Friends 12.  Paddy O'Brien/Seamus Connolly & Charlie Lennon:                  Rigney's Reel/Ambrose Moloney's.    The Banks of the Shannon  13.  Brian Hughes & Dave Sheridan:             Shanahan's HP/Eanach Mhic Coilín/The Leitrim Thrush                However Long the Day 14. Paddy Carty & Conor Tully:                     Dowd's/In Memory of Coleman.  Trad Music of Ireland        15. Dan Brouder & Angelina Carberry:                 Liverpool HP/Mullin's Fancy/Boil The Breakfast/Fallon's Delight.                       Back in Time 16.Brian Conway:   Trim the Velvet/Lord Gordon's..   Consider The Source 17. Willie Clancy:     Plains of Boyle/The Leitrim Fancy.     Seoltaí Séidte 18, Tommy Peoples: The Boy in the Gap/Cronin's.   Trad Irish Music19. Paul Brady:   It's A Beautiful World.   Maybe So 20. The Outside Track: Dark Reels.  Rise Up 21. Bothy Band:   Green Groves of Erin/Flowers of Red Hill.   After Hours  

The High Court in London has upheld the U.S. government's appeal to extradite WikiLeaks founder Julian Assange, a key step towards his rendition to the United States. The Australian publisher faces up to 175 years in prison once he sets foot on American soil.Whether he ever makes it to the United States is still in question. His legal team has indicated they will challenge the ruling, which will inevitably draw out court proceedings and prolong his stay inside Belmarsh Prison. Also of note is the 50-year-old's health. This weekend, it was revealed that he had suffered a stroke in October as a result of the stress of the trial.Two individuals who have been closely monitoring the Assange trial are Pablo Navarette and John McEvoy. Pablo is a British-Chilean filmmaker and the founder of Alborada magazine, an outlet concentrating on Latin American politics. John is an investigative journalist whose work documents the impact of the British national security state on public life. In November, the pair published an article entitled ‘“A Lot of Mistakes”: The Guardian and Julian Assange,' which can be read on MintPress News. Today, they discussed the role that The Guardian, and the mainstream press more generally, have played in persecuting him.It is now known that UC Global – the private security firm hired to protect the Ecuadorian Embassy, where Assange was confined – was secretly spying on their charge, sending the information they gleaned back to the U.S. government. This included security cameras and audio bugs.Guardian journalist Stephanie Kirchgaessner was aware of the spying long before it was made public. Yet rather than blowing the whistle, she instead chose to write highly dubious articles insinuating that he was an agent of Russian malfeasance.The Guardian was one of WikiLeaks's partner organizations, being fed bombshell after bombshell, revelations that helped build its brand and its audience. Yet, far from standing up for free speech, it was in the lead in attacking WikiLeaks and its founder. Of particular note is Luke Harding, who published the passcode to a trove of WikiLeaks documents, an act that the U.S. government claims endangered its representatives around the world.In 2018, Harding also published a viral story that claimed that Assange had secretly met with Trump campaign manager Paul Manafort and unnamed “Russians” while in the Ecuadorian Embassy. The insinuation was that Assange (and Russia) was partly responsible for Trump's shocking election in 2016.From being Assange's partner, the newspaper morphed into “the spearhead of a campaign of vilification by the mainstream media,” Navarette told Lowkey.MintPress News is a fiercely independent, reader-supported outlet, with no billionaire owners or backers. You can support us by becoming a member on Patreon, bookmarking and whitelisting us, and by subscribing to our social media channels, including Twitch, YouTube, Twitter and Instagram.Also, be sure to check out the new Behind the Headlines channel on YouTube.Support the show (https://www.patreon.com/MintPressNews)

This episode is also available as a blog post: https://transnational.live/2021/11/30/john-mcevoy-deathly-silence-journalists-who-mocked-assange-have-nothing-to-say-about-cia-plans-to-kill-him/ --- Send in a voice message: https://anchor.fm/transnational-foundation/message

In Venezuela, Britain is dedicated to supporting the U.S.'s sanctions regime against the country, responsible for more than 100,000 deaths already. McEvoy's work has revealed the existence of a secret British “reconstruction unit” inside Venezuela -- an organization dedicated to overthrowing the Maduro government and planning for a future Venezuela without him.The British government also ordered the Bank of England to freeze around $2 billion worth of gold belonging to the government of Venezuela, on the grounds that it no longer recognized Maduro, instead choosing the unelected Juan Guaidó as the country's legitimate ruler. “Venezuela has been a key target of the hybrid war,” McEvoy explained to Lowkey.McEvoy's academic work at the University of Liverpool focuses on Western interference in Latin America. He recently revealed that the British government had worked tirelessly in the 1960s to prevent the anti-imperialist socialist Salvador Allende from coming to power, and, once he was overthrown in a U.S.-backed coup d'etat, supported fascist dictator Augusto Pinochet. The U.K. government protected Pinochet even after he was removed from office, including paying for his legal fees in his extradition case to Spain, where he was wanted to stand trial for crimes against humanity.Just as Britain protected war criminals in the past, today it is helping to persecute those who expose war crimes, such as Julian Assange.A major thorn in the side of the British establishment, McEvoy is having increasing trouble uncovering documents, his FOIA requests being constantly dismissed in cases he believes to be politically motivated. The FOIA system is supposed to be blind and neutral. However, he told Lowkey, “it has become clear that they have got a blacklist of journalists that they have effectively blocked releasing information to… It's a signal of a receding democracy.”The two also discuss threats to independent journalism at home, specifically the silent campaign to destroy the funding model of alternative media. A group called Stop Funding Fake News was set up in 2019, supposedly in an effort to pressure businesses to remove ads from websites sharing hateful or misleading content. However, McEvoy's research found that the vast majority of its ire was directed at left-wing alternative news outlet The Canary, leading him to conclude that the project was a “thinly veiled censorship campaign against independent media in the U.K.” MintPress News is a fiercely independent, reader-supported outlet, with no billionaire owners or backers. You can support us by becoming a member on Patreon, bookmarking and whitelisting us, and by subscribing to our social media channels, including Twitch, YouTube, Twitter and Instagram.Also, be sure to check out the new Behind the Headlines channel on YouTube.Support the show (https://www.patreon.com/MintPressNews)

In this episode, Hall welcomes John McEvoy, Managing Partner at Tribeca Early Stage Partners (ESP).Headquartered in New York, New York, and founded in 2014, Tribeca ESP is an early-stage venture group primarily focused on pre-A and A-stage companies in FinTech. They have brought together a network of entrepreneurs and business leaders with deep domain expertise in institutional finance and technology. With approximately 50 accredited investors, they have the collective experience and perspective that touches virtually every facet of the institutional finance landscape. While they enjoy socializing, they are not a social club. They are here to invest capital and leverage their strong network to assist the companies in which they invest.John is a passionate, serial entrepreneur who, since 1999, has started three companies focused on using technology to alter the traditional rhythms of the institutional finance space. His first venture, Creditex – a hybrid electronic and voice brokerage trading platform for the credit derivatives market – was acquired by IntercontinentalExchange (ICE) in 2008 for over $600 M. He was also a founder and operating partner of eBond Advisors, which brought financial technology to the product level of a corporate bond – creating a more liquid financial instrument for investors while lowering financing costs for issuers. Finally, John founded a Bermuda-based reinsurance company backed by Wachovia Corp. Prior to his entrepreneurial pursuits, John spent 13 years on Wall Street at PaineWebber, Bankers Trust, and Deutsche Bank in derivative structuring and sales. He has been an active angel investor, board member, and advisor to many young companies. He loves the entrepreneurial environment and process and is always willing to lend a hand or give advice when asked. John advises entrepreneurs and investors in the fintech industry and discusses his investment thesis and some of the startups that fit his thesis.  You can visit Tribeca Early Stage Partners at , and via LinkedIn at .  You can contact John via email at , and via LinkedIn at .  __________________________________________________________________________ For more episodes from Investor Connect, please visit the site at:    Check out our other podcasts here:   For Investors check out:   For Startups check out:   For eGuides check out:   For upcoming Events, check out    For Feedback please contact info@tencapital.group    Please subscribe, share, and leave a review. Music courtesy of .

Copperplate Time374                                                                                                                                     Presented by Alan O'Leary                              www.copperplatemailorder.com                      23rd RETURN TO LONDON TOWN PREVIEW                        1. Bothy Band:   Green Groves/Flowers of Red Hill. After Hours 2. Tony MacMahon: Cúnla/Na Ceannabháin Bhána/Cailleach an Airgid.     Live in Spiddal 3. Urnua:   Myles the Man/Greg the Great/Corrib Suite Crew.           Urnua4. John McEvoy:    The Crib of Perches/The Tinker's Stick/Come Up to the Room..   Pride of the West 5. Joe Derrane:: The Broken Pledge/The Contradiction          Music in the Meadow 6. Niamh Ní Charra: Ceol an Phíobair.  Donnelly's Arm7. Karen Ryan: Limerick Lasses/The Gatehouse Maid/Mountain Top.    The Coast Road 8. Andy Martyn: Jug of Punch/Gan Ainm..   Private Recording9.Mick & Apife O'Brien & Emer Mayock:          The Traveller/Top of the Cliff/The Bride to Bed.                   Tunes from the Goodman Manuscripts 10. James Carty:   Humours of Glendart/Irishman's Heart to the Ladies/The Leprechaun's Fave.   Hiding Daylight in Dark Corners 11. Mick Mulvey & Karen Ryan:          The Coachman's Whip/The Tailor's Thimble/Red Haired Lass..                         Within A Mile of Jamestown   12. Michelle Mulcahy:  Martin Wynne's #2/Humours of Lissadell/Duke of Leinster. .   Suainhneas 13. Tommy Keane & Jacqueline McCarthy:           The Promenade/The Rocky Road to Dublin.                  The Wind Among  the Reeds 14. Derek Hickey & John Keehan:         A Parcel of Land/The Hairy Chested Frog/Kiss Me Kate.               Humours of Scariff15. Matt Molloy & Sean Keane:         Gorman's/The Dawn/Mrs Crehan's Reel.   Contentmant is Wealth 16. John & James Carthy:   Lad O'Beirne's/The Kiltycreen/Snow on the Hill.  The Wavy Bow Collection                                 17. Bert Jansch:   Bonny Portmore.    The Ornament Tree 18. Kieran Collins: Dunphy's Hornpipe:   The Masters Hand 19. Joe Carey: The Market Square of Gort. Private Recording 20. Joe Cooley & Joe Leary:            Humours of Tulla/The Skylark/Roaring Mary. Cooley 21. Angelina Carberry: Mrs MacDonald/Lord Gordon's.           Pluckin' Mad 22. Dezi Donnelly: Conor Tullu's #2/The Cogger's Quilt/Humours of Westport.                                          Familiar Footsteps 23. Bothy Band:   Green Groves/Flowers of Red Hill.  After Hours

Podcast 302 is with a super awesome dude John McEvoy. Johnny is a crazy Irishman that is best known for his life in BASE jumping. He’s owner of BASEGEAR and an instructor at SnakeRiverBase in Idaho. He is brand new to archery and I recently had him out for some days of archery instruction. He’s been on a quest for rad things to do to enhance enlightenment and zen. He’s a reserved dude that has continual layers of interest and amazing stories. 

John McEvoy wrote what has to be the first English-language book for mezcal geeks: Holy Smoke! It’s Mezcal came out in 2014. So when John sent us an email complaining that we “left out the most important part” in our “Tequila vs Mezcal” episode … well, we invited him on to try to convince him that he’s wrong. Will it work? Can we change the mind of the man who goes by Mezcal PhD? Find out in this episode of Agave Road Trip!Find extra photos and related links at agaveroadtrip.comHeritage Radio Network is a listener supported nonprofit podcast network. Support Agave Road Trip by becoming a member!Agave Road Trip is Powered by Simplecast.

This week, join author authors John J.V. McMurrary and Milton Packer, and Associate Editor as they discuss their Perspective article "How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction? A Redefinition of Evidence-Based Medicine." TRANSCRIPT BELOW Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. We're your co-hosts. I'm Dr. Carolyn Lam, associate editor from the National Heart Center and Duke National University of Singapore. Dr. Greg Hundley: And I'm Dr. Greg Hundley, associate editor, director of the Pauley Heart Center at VCU Health in Richmond, Virginia. Dr. Carolyn Lam: Greg, this feature discussion is going to knock you off your seat, because it did me. It's about treatment sequencing in HFrEF and discussing it with some luminaries on the field, Dr. John McMurray and Dr. Milton Packer. You are going to love it. I loved it. But I'm going to make you wait. How about you grab some coffee and let's start with some of the other papers in today's issue first. Dr. Greg Hundley: All right, Carolyn. How about if I go first? I'm going to start with a paper from Dr. Liam Brunham from the University of British Columbia. Well, Carolyn, the high density lipoprotein or HDL hypothesis of atherosclerosis has been challenged by clinical trials of cholesterol ester transfer protein, or CETP inhibitors, which failed to show significant reductions in cardiovascular events. Plasma levels of HDL cholesterol, or HDL-C, declined drastically during sepsis. And this phenomenon is explained in part by the activity of CETP, a major determinant of plasma HDL-C levels. So Carolyn, these authors tested the hypothesis that genetic or pharmacologic inhibition of CETP would preserve HDL levels and decrease mortality in clinical cohorts in animal models of sepsis. Dr. Carolyn Lam: Huh. Interesting. And what did they find? Dr. Greg Hundley: Well, Carolyn, results from both the human UK Biobank and the mouse model experiments suggested that inhibiting CETP may preserve HDL levels and improve outcomes for individuals with sepsis. Dr. Carolyn Lam: Wow. So is this ready for clinical applications somehow? Dr. Greg Hundley: Well, Carolyn, two conclusions from this work. First, high density, lipoprotein cholesterol, a commonly used biomarker for cardiovascular risk assessment, may also predict risk of death from sepsis. And then second, cholesterol ester transfer protein inhibitors that have been tested in clinical trials of cardiovascular disease could be repurposed and studied in clinical trials of sepsis. Dr. Carolyn Lam: Ooh, exciting. Well, Greg, for my paper, I'm going to ask you a question. Have you ever thought about what the temporal changes in medical prevention and adverse outcomes are in patients with symptomatic peripheral artery disease after revascularization? Well, wait no longer. Our next paper addresses that. It's from Dr. Sogaard from Aalborg University Hospital in Denmark and colleagues who identified all patients with a first open surgical or endovascular revascularization procedure in the lower extremities or abdomen in Denmark from 2000 to 2016. And this is what they found. Dr. Carolyn Lam: First, the profile of patients with PAD who underwent lower extremity revascularization changed towards older age and a higher prevalence of comorbidity. Despite increases in age and co-morbidity, medical prevention of adverse events improved substantially over time, particularly in the first part of the study period and among patients who used medications chronically. Dr. Carolyn Lam: Now in contrast, initiating treatment after revascularization increased modestly among treatment-naive patients. Now concurrently, prognosis improved for almost all adverse outcomes in patients of both sexes, all age groups, and in all high-risk co-morbidities. In particular, the risks of myocardial infarction and cardiovascular death declined by more than 40%. Dr. Greg Hundley: Well, Carolyn, are there any other findings with clinical implications here? Dr. Carolyn Lam: Yes. So that was the good news earlier. But despite overall improvements, significant disparities remain. Less than 40% of treatment-naive patients initiated cardioprotective therapy after revascularization, underscoring the need for raising levels of awareness and education in the vascular community, general practitioners and patients of this. Major amputations also remained unchanged and thus more work is needed to understand relationships between the preventive measures, revascularization and amputation. Dr. Greg Hundley: Great summary, Carolyn. My next paper comes from Dr. Rachael Cordina from the Royal Prince Alfred Hospital, University of Sydney. Neurocognitive outcomes beyond childhood in people with a Fontan circulation are not well-defined. So the investigators here aim to study neurocognitive functioning in adolescents and adults with a Fontan circulation and associations with structural brain injury, brain volumetry and postnatal clinical factors. Dr. Carolyn Lam: Okay, you got our attention. What did they find, Greg? Dr. Greg Hundley: Thanks, Carolyn. So participants with a Fontan circulation, without a pre-existing major neurological disability, were prospectively recruited from the Australia and New Zealand Fontan registry. And the investigators found that neurocognitive impairment is common in adolescents and adults with a Fontan circulation and is associated with smaller grey and white matter brain volume. Understanding, therefore Carolyn, modifiable factors that contribute to brain injury to optimize neurocognitive function is paramount. Dr. Carolyn Lam: Indeed. Well, this next paper I want to talk about is the first detailed endothelial cell cysteine-S self-hydrome. Dr. Greg Hundley: Self? S self-hydrome? What is that, Carolyn? Dr. Carolyn Lam: Good. I needed to catch your attention. Let me tell you about it. So in vascular endothelial cells, cysteine metabolism by cystathionine gamma-lyase, or CSE, generates hydrogen sulfide- related sulfane sulfur compounds. And these exert their biological actions via cysteine-S self-hydration of target proteins. So the paper we're talking about today by Dr. Fleming from Goethe University in Germany and colleagues, they aimed to map the S self-hydrome, which is the spectrum of proteins targeted by this hydrogen sulfide-related sulfane sulfur compounds, or H2Sn, in human endothelial cells. And they did this using liquid chromatography and tandem mass spectrometry. Dr. Carolyn Lam: So here's what they found: vascular disease was associated with mark changes in the S self-hydration of endothelial cell proteins involved in mediating responses to flow. Integrins were most effected by S self-hydration and the modification of beta-3 integrin resulted in reshuffling of the intramolecular disulfite bonds to preserve its extended and open confirmation. Loss of beta-3 integrin self-hydration, on the other hand, inhibited endothelial cell adhesion, impaired mechanosensing and attenuated flow induced phase with dilation. Thus, short term H2Sn supplementation could improve vascular reactivity in humans, highlighting the potential of interfering with this possibly to treat vascular disease. Dr. Greg Hundley: Very nice, Carolyn. You know, just more from the world of hydrogen sulfide and endothelial function. Thanks so much. Well, the next paper I have comes to us from Dr. John McEvoy from Johns Hopkins University School of Medicine. So Carolyn, recent clinical guidelines support intensive blood pressure treatment targets. However, observational data suggests that excessive diastolic blood pressure lowering might increase the risk of myocardial infarction. Therefore reflecting, does a J or U-shaped relationship exist when we're following the treatment of diastolic blood pressure? So Carolyn, these authors analyzed 47,407 participants from five cohorts with a median age of 60 years. First to corroborate prior observational analysis, the authors used traditional statistical methods to test the shape of association between diastolic blood pressure and cardiovascular disease. Dr. Carolyn Lam: Okay. So was it J or U? Dr. Greg Hundley: Okay, Carolyn. So interesting, traditional observational analysis of the cohorts suggested a J-shaped association between diastolic blood pressure and myocardial infarction. However by contrast, linear MRI analyses demonstrated an adverse effect of increasing diastolic blood pressure increments on cardiovascular disease outcomes, including myocardial infarction. Furthermore non-linear MRI analyses found no evidence for a J-shaped relationship. Instead confirming that myocardial infarction risk decreases consistently per unit decrease in diastolic blood pressure, even among individuals with low values of baseline diastolic blood pressure. So Carolyn, in answer to you, no, the J or U-shaped curve does not exist. Dr. Carolyn Lam: I suppose depending which way you look at it. Very interesting. Well, let's finish up with what else is in today's issue. There's an AJ update by Dr. Elkin on COVID-19 at one year, the American Heart Association president reflect on the pandemic. A white paper by Dr. Zannad on challenges of cardio kidney composite outcomes in large scale clinical trials. A research letter by Dr. Kass on  the reduced right ventricular sarcomere contractility in HFpEF with severe obesity. Another research letter by Dr. Messas on the feasibility and performance of non-invasive ultrasound therapy in patients with severe symptomatic aortic valve stenosis. A first in human study. Dr. Greg Hundley: Right, Carolyn. So I've got an exchange of letters from Dr. Vazgiourakis  addressing a prior publication entitled Right Heart Dysfunction in COVID-19 Patients: Does Mechanical Ventilation Play an Additional Role? And then finally, an exchange of letters from Drs. Carrizales-Sepúlveda and Topalisky regarding the prior paper, The Spectrum of Cardiac Manifestations in COVID-19. Well, Carolyn, I'm really excited to get to that feature that you explained to us right at the beginning. Very exciting. Dr. Carolyn Lam: So am I. So am I. Thanks, Greg. Dr. Carolyn Lam: Wow. Today's feature discussion could not be more star-studded in my point of view. We are talking about the very, very hot topic of how do we sequence treatments in heart failure with reduced ejection fraction now? A really hot topic because just last year in 2020, we suddenly got a bonanza of positive trials and everybody's grappling with how to put it all together. Dr. Carolyn Lam: Now who better than the two authors I'm going to talk to today, Professor John McMurray from University of Glasgow and Professor Milton Packer from Baylor University Medical Center in Texas. So welcome both. John, Milton, I'm almost tripping over myself to talk about this because this is an amazing perspective piece. Everybody must get your hands on it and even look at the figure while you're listening to this. We're going to divide today's discussion into just three simple questions. Why do we need a new sequencing approach? How in the world do you come up with a new sequencing approach? Based on what? And finally, what is that new approach that you're both proposing? So maybe I'll start off with you, John. What's wrong with what we've been doing? Dr. John McMurray: So Carolyn, I think we've maybe neglected the fact that while we think of, for example, cancer as something that's incredibly urgent to diagnose and to treat as fast as possible, to give the patient all those life-saving therapies, we haven't had the same urgency in our treatment with heart failure. And our existing approaches, as you know, being largely one of start with the first treatment that was ever tested in the trial, up titrate to the pill dose, take your time, then on the second, third and so on. And of course, what that means is that it takes months for patients to be treated with all of the fantastic life-saving options that we have available for them. And we know that that's failing. Dr. John McMurray: We've seen from numerous registries, CHAMP registry in particular springs to mind, where that's simply not happening. It's probably taking too long. It's too complicated for both the doctor and the patient, and we need to change it. And I suppose Milton will tell you his view, but I think my view and I think his as well, was that the SGLT2 inhibitor story really brought this question, I think, to the fore because here is our fourth life-saving drug that if we do things the same way might not get started for six months. And we really felt that we need to rethink what we're doing. Milton, I'm sure, will say whether he agrees with that. But I think that was sort of where the starting point was. Dr. Carolyn Lam: Great. But if I could interject a bit, so now we're talking about that left side of the panel, where in your beautiful article where you're showing, we start with ACE inhibitors and ARBs, and then go on to beta blockers and mineralocorticoid receptor antagonists, and so on. I would love to know, and Milton I'm sure you'll add, is it the sequence that's wrong? Or is it really just the timing? Or the fact that we're just all too lazy? What do you say to people who go, "But that's how the trials were done." Especially because you guys both led those amazing trials of ARNIs and SGLT2 inhibitors. It's just awesome. Dr. Milton Packer: So Carolyn, what's really amazing is that everyone assumes that that's how the trials were done. But two things, one, just because we did things in a certain way, developed things in a certain way, doesn't mean we have to prescribe them in a certain way. I mean, we developed digitalis before all of them and so does that mean we need to use digitalis in everyone? But a lot of the early trials, all the patients were, or most of the patients were, on cardiac glycosides. Dr. Milton Packer: There are four things that we've learned from the large-scale clinical trials. One is the order of drugs does not matter with respect to efficacy. The beta blockers work the same whether people are getting ACE inhibitors or not, MRAs are not effected by background therapy. Neither is neprilysin inhibitors. They work pretty much the same regardless of background therapy, so you don't have to sequence them in the order in which they were developed. Dr. Milton Packer: Two is low doses, low starting doses of these drugs seem to work amazingly well, perhaps surprisingly well. And the third thing is that they work very early. So in a lot of the clinical trials, nearly all the trials that were carried out, there was a meaningful separation of the curves and in effect size in the first 30 days of all of these trials. And in many of the trials, in the first 30 days, patients were still on the starting dose. Hadn't been uptitrated. Dr. Milton Packer: The last point is that these drugs can influence each other's safety profiles. So the result of all of this was for us to rethink what the sequence should be based not on how the drugs were developed, but how they might be most logically used with respect to relative efficacy, safety and ease of use. Dr. John McMurray: So, Carolyn, to go back to your question then is sort of what Milton is saying is that it's a bit of both of the things you asked about. It is about timing, but it's also about the order of the drug. And that last point Milton made is very important about the potential synergies in terms of making it easier to use treatments, but timing is critically important as well. I mean, we do tend in the conventional approach to therapy recommended in the guidelines to perhaps spend too much time trying to reach that target dose, and then doing that before moving on to the second drug. So again as Milton pointed out, if you're getting early benefit from all of these treatments, fundamentally what you want is as many of these treatments started as quickly as possible as you can do safely. And that may be facilitated by some of the synergies between treatments as we, I think, rather provocatively suggested in the new algorithm, might even be possible to start two treatments at once. Dr. Carolyn Lam: Okay. Now I know everybody's really, really wondering what that new algorithm is, but I'm going to lengthen the pain a little bit more because this is critically important. You've already started discussing the how did you come up with an algorithm. It seems a lot of, yeah, very reasonable approaches, but could you give us specific examples of actual scientific interrogation of the data from the trials that you've led, frankly, to show us these points, that maybe support that we can come up with a reasonable new approach? Those points that Milton very rightly put, the treatment benefit of each class is independent. Give us some examples of that. The dose issue, the side effects, how one could help in that too. Could you give us some examples? Dr. Milton Packer: Oh, my God. So let me say that there's so many pieces of evidence and please read the article. We try to summarize as much of them as possible. But in all of the major clinical trials, there was a separation that occurs within 30 days. That's true across every single major trial. Anyone who thinks that the treatment effects of these drugs are delayed, that it takes months to evolve, we're getting statistical significance within two to four weeks across all of the drugs. Dr. Milton Packer: Second is, in many of the trials, for example, COPERNICUS trial with carvedilol, the trials with MRAs, even the trials with ACE inhibitors, during that first 30 days when the curves were separating, patients hadn't been uptitrated. They started on low doses and remained on relatively low doses and the curves were separating. So we knew that the drugs had early effects at low doses, low starting doses. And we also have randomized trials that really tell us that if you go to high doses for some of these drugs, you get a little bit more benefit, but you don't get as much benefit as starting another drug with a different mechanism at a low dose. Dr. Milton Packer: And lastly, we know that some of these drugs actually prevent the side effects of others. There's evidence that neprilysin inhibitors and SGLT2 inhibitors mitigate the hyperkalemia produced by spironolactone and aplerno. So these are just a few examples. Dr. John McMurray: Sorry, Carolyn. To add a couple more, we obviously know that the treatments work independently. We primarily knew that from subgroup analyses, but also from trials like RALES for example, where spironolactone was tested in addition to an ACE inhibitor, but very, very few patients were on a beta blocker. Subsequently we tested different a MRA in patients who were taking both an ACE inhibitor and a beta blocker, and the benefit was essentially the same. And of course, our very first trial with an ACE inhibitor, the CONSENSUS trial, was actually done in a population where more than half of the patients were on a very large dose of an MRA. So you can sort of put all the trials together in a type of jigsaw and figure out that these drugs all clearly work independently. Dr. John McMurray: And then maybe the only other thing I would mention, because it's perhaps relevant to the new algorithm, is that we do have another key trial, which is, a trial I think often forgotten about, the CIBIS III, which was a study that tested whether or not you could start treatment with either a beta blocker or with and ACE inhibitor in patients with HFrEF, showing that you could start with a beta blocker in patients who had not yet received an ACE inhibitor and do that safely and efficaciously. So there's a lot of material out there that you can sort of put together to answer all of these questions. Dr. Carolyn Lam: Great. And now drum roll. Okay. What is the new algorithm? John, you want to introduce it? Or Milton? Up to you. Dr. Milton Packer: John can start. That's fine. Dr. Carolyn Lam: Well, which one, Carolyn? I suppose the one in the Circulation article is a three-step algorithm. It starts with the combination of a beta blocker, based as I mentioned, so there's three plus an SGLT2 inhibitor. So again, thinking about synergies, thinking about tolerability, thinking about size of effect and thinking about repetity of onset of benefit. So I think most of us would agree, beta blockers are incredibly effective treatments, life-saving treatments, reduce the risk of sudden death. We know that you can start a beta blocker safely as first-line therapy. We do know that there may be more intolerance in patients who are volume overloaded. So why not give a treatment that has a modest, initial diarrhetic effect when you're starting the beta blocker? In other words, the SGLT2 inhibitor. SGLT2 inhibitors work extremely quickly. There's no dose up titration needed. So they seem like the perfect combination to start with. Dr. Carolyn Lam: In step two, we suggested moving then to sacubitril valsartan, which in itself is two more drugs combination of an angiotensin receptor blocker and their prolines inhibitor. And then there's the third and final step. We suggested using a mineralocorticoid receptor antagonist. But Milton and I have had a lot of discussion about this. I think we're not saying that all those are necessarily the three steps for all patients. There may be different approaches in different people depending on patient's characteristics. But really the point here was, the provocative statement was we should be able to do this quickly in all patients. And this in fact was an approach to get all four of those drugs started potentially within four weeks. Dr. Milton Packer: So Carolyn, the mantra here, our motto going forwards, is four drugs in four weeks. Dr. Carolyn Lam: Okay. Dr. Milton Packer: An angiotensin receptor blocker, a beta blocker, an MRA, an SGLT2 inhibitor. Four drugs in four weeks. And if you're going to start all four drugs in four weeks, in all honesty, the order probably doesn't matter that much. John and I happen to think that if you have to define a first step, a combination of a beta blocker and an SGLT2 inhibitor simultaneously as step one makes a lot of sense. And then you can follow up with sacubitril valsartan and an MRA. Dr. Milton Packer: But here's the thing that's really important: do not take months to follow up. What we're proposing in this algorithm is you start a beta blocker and an SGLT2 inhibitor on day one, and you then follow through with sacubitril valsartan and an MRA within the next couple of weeks. But here's what's really important and we really need to emphasize this: this is a algorithm that assumes that someone's not on any of these drugs already. And of course, most of these patients are taking some of these drugs already. But the other thing that's really important is that we're also assuming that physicians are being very meticulous about background use of diuretics, so that patients really have to be maintained in a clinically euvolemic state in order to make this algorithm work. Dr. Carolyn Lam: Okay, well, I'm picking myself off the floor because it certainly was provocative. I love it. I love it for that. It's the first time I've ever seen any algorithm start with a beta blocker and SGLT2 inhibitor. You first go, "Where's the ACE and how come the new kid on the block is right on top?" So I really like that because it must challenge our current thinking. In other words, if we just look at the data for what it is, let's see how we could think it over. So salute you for that. But let me just press on a little bit. So four drugs in four weeks. That's really great. Are there any particular patients you may say the ARNIs come on top or the MRAs? Specific situations or...? Dr. Milton Packer: Well, Carolyn, as John has already said, the physicians need to understand the principles, but the application of those principles have to be individualized. So if a patient has a borderline blood pressure, you would probably be well advised to put the MRA before sacubitril valsartan. Depending on renal function, you may decide to advocate one drug a little bit earlier or preferentially compared to another. There are hundreds of individualized nuances, but to get tied up in these is to miss the point of our paper. The point of our paper is that we need to do things quickly... Four drugs, four weeks... And we need to not rely on our historical testing in order to determine the optimal sequence. If you embrace those conclusions, then patients and physicians can individualize their care to the greatest optimal degree. But our current approach, which is a historically-driven algorithm that takes six months to execute, it doesn't work. Dr. John McMurray: Carolyn, we obviously did give a lot of thought to the initial treatments, and we did realize that it would potentially be a surprise to people. But just to reiterate, I don't think there's much debate about the incredible benefits of beta blockers, the size of that benefit. We know that the benefit is apparent within 30 days. So Milton and we had Henry Krum's very nice paper about that in JAMA from the COPERNICUS trial, but we're seen it in the other trials. You know that SGLT2 inhibitors have had early benefit. You think about these two drugs being used in a newly presenting patient with HFrEF, probably don't even need to do any electrolyte monitoring, provided your patients not volume overloaded or recently decompensated. That patient's very unlikely to have any significant intolerance to these two treatments. Dr. John McMurray: They don't, in those sorts of patients, substantially reduced blood pressure in either drug, beta blockers certainly don't affect kidney function. SGLT2 inhibitors have minimal effect on kidney function. If your GFR is relatively normal, you probably don't even need to check it. And of course, there's no effect on potassium. So in terms of getting two treatments onboard quickly that will have a rapid benefit, are likely to be well-tolerated in the type of patient that we just described, and where they might have monitoring necessary is minimal, then this seemed to be the best option. And as Milton said thereafter, it's maybe less important what order you do it in as opposed to the speed with which you do it. And you're right, you would definitely probably tailor this approach according to the patient characteristics, but this was a general starting point to stimulate debate, which it seems to have done. Dr. Milton Packer: So Carolyn, there's something important. If you believe in what we've proposed, then at the end of four weeks, every patient with heart failure and reduced ejection fraction would be on low starting doses or four foundational drugs. Our estimate is if doing that would provide them with a substantial benefit, maybe 70, 75% of the benefit of bringing all of those doses to target doses. And if you can do that, you can do all four drugs at starting doses at four weeks and provide that magnitude of benefit really quickly? That has a big impact on patients. And that has a big impact on public health. Dr. Carolyn Lam: Wow. Just thank you so much for igniting this debate. I wish we could go on forever. I just had to share that when we editors looked at this paper, it did spur a very robust debate. But as you can see, we're publishing it as you've proposed it because we do see where you're coming from. It is very interesting. And I just want to reiterate what you both just said, to listeners out there, remember this is referring to a patient who is compensated. Diuretics are still part of it. Remember that the key message is to get everyone on the four foundational therapies within four weeks. And I just love the way you pushed the boundaries with this. Really, really appreciate it. Milton, you look like you want to say something else. If you'd like closing words, I'd love to... Dr. Milton Packer: We really thank Circulation for having the courage to do this. And please understand, John and I strongly feel that this is the start of a debate. This is the start of a discussion. This algorithm is a proposal to get people to start thinking differently. This is not the final word on the subject by far. We think this is the beginning of a very important discourse that will evolve over the next year or more. And we just wanted to remind people what the clinical trial evidence actually shows about these drugs, because we think it has been frequently misunderstood much to the detriment of patients with heart failure. Dr. Carolyn Lam: Yes. And John, any last words? Dr. John McMurray: I would go back to where I started, Carolyn. In a way, what's important here is to inject a sense of urgency back into the way in which we treat patients with heart failure and reduced ejection fraction. It deserves that sense of urgency, as I mentioned that, for example, cancer does. And also thank you for summarizing, I think, what we tried to get across absolutely accurately. Dr. Carolyn Lam: Okay. So John, Milton, so far I take it. I take your points well, but as a practitioner, what I would do, frankly, is if I have a patient that I'm starting a beta blocker and an SGLT2 inhibitor, I would surely just start an ACE inhibitor perhaps, or ARNI, at the same time. I don't see why I need to delay it. How about that? Even faster? Dr. John McMurray: Okay, well, I'll let Milton answer the faster, but I would say one thing, Carolyn, the new algorithm doesn't mention ACE inhibitors or angiotensin receptor blockers as a monotherapy. Because I think those days are gone. I really do think that we shouldn't go through that cycle of starting a RAS blocker, uptitrating it, then switching to an ARNI because that's a waste of time. You're delaying the introduction of life-saving therapy. And this is the whole point to, again, get that sense of urgency across in implementing all of these treatments as quickly as possible. Dr. Milton Packer: And Carolyn, if you want to go faster, that would be fine. Maybe we shouldn't have proposed four drugs in four weeks. We should have proposed four drugs in four days. But Carolyn, I think that changing the way people think is a gradual process. Perhaps four drugs in four weeks is a good starting point. If everyone feels comfortable with that and understands why we are proposing that, then in another six months or so, Circulation can invite John and I to come back and propose four drugs in four days. But let's see what happens. Dr. Carolyn Lam: Kudos. Thank you so much. Well, thank you once again, John and Milton. That was an incredible discussion. A beautiful paper. Dr. Carolyn Lam: Thank you so much, listeners. I'm sure you enjoyed that as much as I have or probably more. But thank you and please don't forget to tune in again next week. From Greg and I, here's Circulation on the Run. Dr. Greg Hundley This program is copyright of the American Heart Association, 2021.  

                               Copperplate Time 331                                                                           presented by Alan O'Leary                         www.copperplatemailorder.com              Preview of 22nd Return to London Town Festival                         1. Bothy Band:   Green Groves/Flowers of Red Hill. 1975 2. Danu:  McCahill’s/Doherty’s/Gan Ainm. The Road Less Traveled 3. Martin Hayes & Dennis Cahill:   The Lane to the Glen/Fahy’s.                            Welcome Here Again4. Pat Walsh:   The Forgotten Fling/Mrs Galvin’s.             Simply Whistle                                                             5. Kevin Burke: The Gallowglass Jig/Coach Road to Sligo.                  Sligo Made 6. Paul Brennan:   The Bonny Labouring Boy.   Airs & Graces7. John McEvoy:   The Crib of Perches/The Tinker’s Stick/Come up To the Room.                              The Pride of the West 8. We Banjo 3:  The Buunch of Green Rushes/Salt Creek.                         Live in Galway 9. Maeve Donnelly & Tony McManus:  Return to Camden                      Town/THE Girl Who Broke My Heart.    Flame on the Banks 10. Gatehouse:   Joe Ryan’s Mazourka/Buckley’s Fancy/             The Laurel Tree.  Tus Nua                                                     11 Dervish:    Gypsies/Tramps & Thieves.    Travelling Show 12. . The Gavin’s:    Touch Me If You Dare/Callaghan;s/                 Greenfields of America.     The Quiet House 13. London Lasses:   Humours of Castlefinn/Eileen O’Brien’s/                The Enchanted     Lady.   Enchanted Lady 14. John & James Carthy:   Corkscrew Hill/The Spectacle Bridge/                           The Cloughan Jig.  The Wavy Bow Collection15. Le Cheile:   Maud Miller.    Out of the West 16. Liam Kelly:  Maids on the Green/Tonra’s/Billy McCormick’s.                                 Sweetwood 17. Angelina Carberry & Dan Brouder:          McCarthy’s/Basket of Oysters/East of Glendart.  A Waltz for Joy 18. Noreen O’Sullivan:   Eddie Moloney’s/Tae in the Bog/               Jimmy Kennelly’s.   The Quiet House 19. The Friel Sisters:   The Ranafast Jig/Statia Donnelly’s/             My Former Wife.     Before The Sun 20. Peter McAlinden:   The Lmestone Rock/Josie McDermott’s.                     Happy to Meet                                                                  21. Karen Ryan:  The Limerick Lasses/Gatehouse Maid/                                  The Mountain Top.       The Coast Road               22. Bothy Band:   Green Groves/Flowers of Red Hill. 1975

On this first episode of the OpenFin MVP podcast, John McEvoy explains how he decided to become the first investor in OpenFin. He also discusses the results of the Tribeca Early Stage Partners COVID-19 survey, what entrepreneurs should do in this environment, whether grads should pursue a career on Wall Street, and what you should be drinking in these turbulent times.

John McEvoy, current Head Coach and Assistant Director of Admissions at Malvern Prep, joins this episode. An old friend of Bill Leahy's from his playing days as a Captain and All-Pro with the Philadelphia Wings, John shares stories from his playing career and takes us through his various stops as a young coach before his long career at his alma mater, Malvern Prep. Topics discussed include Coach Mac's "mortal sins", helping kids deal with adversity, building a nationally-ranked program, and reminding lacrosse coaches that this is a game and it should be fun.

Holy Smoke! It'ts Mezcal! Author John McEvoy explains its monster comeback.

Every week the show host John Siracusa talks with amazing fintech leaders and entrepreneurs, through conversation uncovers the amazing stories behind them, their creations and the most important topics in fintech. You can subscribe to this podcast and stay up to date on all the stories here on iTunes, Google Play, Stitcher, Spotify and iHeartRadio In this episode the host John Siracusa chats with John McEvoy, Managing Director of Tribeca Angels.  Tribeca Angels is a collection of current and former finance professionals, entrepreneurs, and technologists focused on assisting and investing in seed or early stage companies in the FinTech space.  John McEvoy is a successful entrepreneur exiting 3 companies, CrediteX, being one that sold to ICE (NYSE parent) for $625,000,000 in June, 2008.     Tune in and Listen.   Subscribe now on iTunes, Google Play, Stitcher, Spotify and iHeartRadio to hear Next Tuesday's episode with Gilles Gade from Cross River Bank.   About the host:   John is the host of the 2x weekly "Bank On It” podcast recorded onsite at the Carpenter Group offices, which is a strategic branding and positioning firm in the financial services industry. He's a highly sought after fintech, VC and financial services industry enthusiast and connector. He's in the center of the fintech ecosystem keeping current with the ever - innovating industry.   Follow John on LinkedIn, Twitter or Medium

This is a special release and extended episode.  The host John Siracusa recorded on site during Coindesk, Consensus Invest 2018 in NYC and interviewed speakers from the event.     Some of the speakers at the event were Jeff Sprecher founder and chairman of Intercontinental Exchange/ ICE, Jay Clayton, Chairman, U.S. Securities and Exchange Commission.  There were many Crypto/investment strategies shared and you can watch the videos from the event here.      In this podcast episode we're releasing our interviews with the following event speakers.   Nolan Bauerle - Coindesk Jacob Donnelly - Coindesk Demetrios Skalkotos - Ledger Jeremy Drane - Libra Caitlin Long   Subscribe now on iTunes, Google Play, Stitcher, Spotify and iHeartRadio to hear Thursdays episode with John McEvoy from Tribeca Angels.   About the host:   John is the host of the 2x weekly "Bank On It” podcast recorded onsite at the Carpenter Group offices, which is a strategic branding and positioning firm in the financial services industry. He's a highly sought after fintech, VC and financial services industry enthusiast and connector. He's in the center of the fintech ecosystem keeping current with the ever - innovating industry.   Follow John on LinkedIn, Twitter or Medium  

We speak with Dr John McEvoy about his work tracking Asian elephants in Myanmar. We discuss the threat that that elephants are facing from poachers and how elephant-human relationships in local areas are key to keeping the elephants safe.

Episode 018-  Ed Draves didn't know much of anything about tequila or mezcal when he went to Oaxaca, Mexico on a trip with his church. Over the years, he has become an expert on the subject and has gone back to Mexico several times to witness the production of this spirit. In this episode, you'll learn the difference between tequila and mezcal.  You'll get the basics on what to look for if you are a newbie. After listening, you'll also understand why Ed keeps going back! During the interview, Ed discussed Wahaka Mezcal, Rey Campero Mezcal,  and the blog Dave Miller's Mexico.  If you want to learn more about mezcal, the books that Ed mentioned are "Holy Smoke, It's Mezcal by John McEvoy" and "Mezcalaria, The Cult of Mezcal, by Ulises Torrentera".  Recently, liquor.com did a slideshow called The Essential Places for Drinking Mezcal in Oaxaca. There you can see a photo of Torrentera's bar that Ed described and, if you ever find yourself there, now you have recommendations on where to go! During the interview, Ed mentioned gusano salt which is made with worms and some use it to accompany their mezcal drinking.  If you'd like to dig into more on that, here is more information. The Guys and Food newsletter gives you delicious recipes, helpful kitchen hacks, and other things that any food guy will find useful. Some of the things in the newsletter will be exclusive, which means it won't make it on the podcast or blog. Sign up for the newsletter, you'll be glad that you did! (Don't worry, your contact information will never be sold or made available to any other person or organization.) Remember to subscribe to the Guys and Food podcast in Apple Podcasts, Stitcher, GooglePlay, and Tunein Radio.  In social media you can find us on Facebook and Twitter!  Please feel free to reach out with your questions or comments.  You can do that by clicking on the Contact button, email me at gabe@ guysandfood.com, or call the listener line at 716-427-GUYS (4897).

Dave and Cathy walk home from the latest Marvel movie with special guest walker John McEvoy.  They entered with varying expectations - John knew nothing about it, Cathy is done with Marvel and Dave just watched all the Marvel movies in a row.  They left.... with the same opinion! #Unity SPOILERS from 11.28 onwards. See acast.com/privacy for privacy and opt-out information.